Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omega-3 fatty acids are polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), derived from fish oil. In the context of Sjögren's syndrome, they have been investigated by Hawler Medical University for their anti-inflammatory properties. The mechanism involves modulating prostaglandin metabolism, specifically shifting the balance toward the synthesis of anti-inflammatory prostaglandins and inhibiting the production of pro-inflammatory mediators. A Phase 2/3 clinical trial (NCT05005806) conducted at Rizgary Teaching Hospital in Erbil, Iraq, demonstrated that dietary omega-3 supplementation significantly improved dry eye and dry mouth symptoms and led to the normalization of salivary flow rates in patients with Sjögren's syndrome over a two-month treatment period.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 fatty acids (Hawler Medical University).